Do Ozempic studies stop just before weight regain kicks in?

What did @thatirishdietitian actually say?

The dietitian made a sweeping claim: "neither Ozempic nor a healthy diet and exercise have been shown to produce long term weight loss results." They were pushing back on someone defending Ozempic, but in doing so, they painted both drug-based and lifestyle-based approaches with the same brush. The argument seems designed to land as a gotcha, but it collapses under scrutiny the moment you look at what the actual trial data shows.

To be fair, there is a real and important point buried in here about weight regain after stopping GLP-1 medications. That part of the argument has genuine evidence behind it. But the framing, that neither approach "works long term," overstates the case in a way that could mislead nearly a million viewers into thinking there is simply no effective tool for weight management at all.

Does the science back this up?

Partially, and only partially. The claim about lifestyle interventions is the stronger of the two. The Look AHEAD trial (Wing et al., 2013, New England Journal of Medicine) followed over 5,000 people with type 2 diabetes for nearly a decade using intensive lifestyle intervention. Weight loss was modest and declined over time, though the intervention did produce sustained benefits in fitness and glycemic control. So yes, long-term weight maintenance through diet and exercise alone is genuinely hard, and the evidence supports that.

The Ozempic side is more complicated. The SUSTAIN-6 trial (Marso et al., 2016, NEJM) and the STEP 1 trial (Wilding et al., 2021, NEJM) both showed meaningful weight loss of around 15 percent of body weight on semaglutide over 68 weeks. Critically, the STEP 4 trial (Rubino et al., 2021, JAMA) showed that stopping semaglutide led to regain of about two-thirds of lost weight within a year. So the medication works while you take it, but the weight loss is not durable after stopping. That is a legitimate limitation. It does not mean the drug does not work.

What did they get right and wrong?

They got one thing right: weight regain after discontinuing GLP-1 medications is a real, documented phenomenon. The caption accompanying this video actually explains it better than the transcript does, noting that studies often end at the weight plateau rather than following patients through the regain phase. That is a fair critique of how drug trials are sometimes designed and communicated to the public.

What they got wrong is the logical leap from "hard to maintain" to "does not work." A medication that produces 15 percent body weight reduction while in use absolutely "works." Whether it is a practical long-term solution for every patient is a separate clinical question. Conflating those two things is misleading.

They also made a false equivalence between Ozempic and lifestyle intervention as if both fail in the same way and to the same degree. They do not. The mechanisms, the magnitude of effect, and the conditions under which they fail are all different.

What should you actually know?

Here is the honest picture. GLP-1 receptor agonists like semaglutide produce significant weight loss in clinical trials, often more than any lifestyle intervention tested at scale. The limitation is that this effect appears to depend on continued use. When patients stop the medication, appetite regulation shifts back and weight returns, as documented in the STEP 4 trial and the SURMOUNT-4 trial for tirzepatide (Aronne et al., 2024, JAMA).

Lifestyle interventions do produce weight loss, but long-term maintenance is difficult for most people. That is not a moral failure, it reflects the biology of energy homeostasis. Neither approach produces effortless permanent results for the majority of people, which is exactly why obesity medicine specialists often discuss long-term or indefinite use of GLP-1 medications as a chronic disease management strategy rather than a short course.

The takeaway is not "nothing works." It is that weight management is complex, both options have real but conditional benefits, and framing this as a simple failure of all available tools does not serve patients well.